Overview

Deep Vein Thrombosis Treatment With the Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients Using a Strong CYP 3A4 Inducer

Status:
Completed

Trial end date:
2011-06-01

Target enrollment:

Participant gender:

Summary

This is a multicenter, cohort study evaluating an adapted rivaroxaban dose regimen in patients with acute, proximal deep-vein thrombosis (DVT) or acute pulmonary embolism (PE) who concomitantly use a strong cytochrome P450 isoenzyme 3A4 (CYP 3A4) inducer for the entire 3-month study duration.

Phase:

Phase 2

Details

Lead Sponsor:

Bayer

Collaborator:

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Treatments:

Cytochrome P-450 CYP3A Inducers
Factor Xa Inhibitors
Rivaroxaban